Provider Briefing: The Bicillin L-A Shortage in 2026

The shortage of Bicillin L-A (Penicillin G Benzathine) continues to present significant challenges for clinicians managing syphilis, streptococcal infections, and rheumatic fever prophylaxis. As the sole FDA-approved long-acting injectable penicillin, its limited availability directly impacts treatment protocols and patient outcomes.

This article provides a comprehensive overview for healthcare providers and prescribers, including the current supply status, clinical recommendations, imported alternatives, and practical tools for navigating the shortage.

Timeline: How We Got Here

Understanding the timeline is critical for contextualizing the current supply picture:

• Mid-2023: The FDA first listed Bicillin L-A as being in shortage. Contributing factors included surging syphilis rates and manufacturing constraints at Pfizer, the sole domestic manufacturer.
• June 2023: Pfizer projected supply recovery by Q2 2024.
• January 2024: The FDA exercised enforcement discretion to authorize temporary importation of Extencilline (benzathine benzylpenicillin injection, powder for suspension) from European manufacturers.
• Q2-Q4 2024: Supply remained constrained despite Pfizer's production efforts. Extencilline helped bridge gaps in some regions.
• July 10, 2025: Pfizer issued a voluntary recall of multiple lots of Bicillin L-A (1.2 million and 2.4 million unit prefilled syringes) due to particulates identified during visual inspection. This recall dramatically worsened the shortage.
• March 6, 2026: The FDA authorized temporary importation of Lentocilin (benzathine benzylpenicillin tetrahydrate) due to ongoing limited availability and extended recovery of Bicillin L-A.
• Current projection: The shortage is expected to continue through Q3 2026.

Prescribing Implications

The shortage has significant implications across several clinical scenarios:

Syphilis Treatment

Benzathine penicillin G (BPG) remains the only recommended first-line treatment for all stages of syphilis per CDC guidelines. This is particularly critical for:

• Pregnant patients: BPG is the only recommended treatment for syphilis during pregnancy. No adequate alternative exists. Desensitization and treatment with penicillin should be pursued if the patient has a documented allergy.
• Congenital syphilis prevention: Maternal treatment with BPG is essential to prevent transmission to the fetus.
• Neurosyphilis: Note that Bicillin L-A is NOT indicated for neurosyphilis — IV Penicillin G is the standard treatment.

Alternative Regimens When BPG Is Unavailable

When no benzathine penicillin product is available, the CDC recommends the following alternatives for non-pregnant adults:

• Doxycycline: 100 mg PO BID for 14 days (primary/secondary syphilis) or 28 days (late latent/tertiary)
• Ceftriaxone: 1-2 g IM or IV daily for 10-14 days

These alternatives carry limitations including lower-quality evidence, adherence challenges, and cross-reactivity concerns. Document the clinical rationale for alternative therapy in the medical record.

Streptococcal Pharyngitis and Rheumatic Fever Prophylaxis

For streptococcal pharyngitis, widely available oral alternatives (Amoxicillin, Penicillin V) should be used preferentially during the shortage. For rheumatic fever prophylaxis patients on chronic BPG injections, consult with cardiology or infectious disease regarding schedule modifications or alternative prophylactic regimens.

Current Availability Picture

Supply remains very limited as of Q1 2026. Key considerations:

• Domestic supply (Bicillin L-A): Severely constrained. Some lots are reaching pharmacies, but quantities are insufficient to meet demand.
• Extencilline: Available through some healthcare facilities and public health departments since January 2024. Comes as powder for reconstitution — providers should familiarize themselves with the preparation instructions.
• Lentocilin: Newly authorized as of March 2026. Distribution is ramping up through healthcare systems and public health channels.

The CDC strongly encourages clinicians and STI programs to monitor local supply and prioritize BPG for the highest-need patients, particularly pregnant individuals with syphilis.

Cost and Access Considerations

Bicillin L-A pricing remains significant, with no generic alternative available:

• 2.4 million unit syringe: $813-$1,037 per unit (retail)
• 1.2 million unit syringe: ~$397 per unit
• 600,000 unit syringe: ~$230 per unit

For uninsured patients, Pfizer RxPathways (1-844-989-PATH / pfizerrxpathways.com) may provide access to Pfizer medications at reduced or no cost. Public health department STI clinics typically provide syphilis treatment at no cost regardless of insurance status.

The imported alternatives (Extencilline, Lentocilin) are generally being distributed through institutional channels and may not carry the same retail pricing structure.

Tools and Resources for Providers

The following resources can help you manage the shortage in your practice:

• Medfinder for Providers: Search for pharmacies and distributors with current Bicillin L-A stock. Helps practices and clinics locate available supply.
• CDC STI Treatment Guidelines: Current clinical guidance on alternative regimens during BPG shortage
• FDA Drug Shortage Database: Official shortage status and manufacturer communications
• State/local health departments: Many are coordinating BPG allocation and distributing imported alternatives

For patient-facing guidance you can share, see: How to Find Bicillin L-A in Stock Near You.

Looking Ahead

Pfizer has not committed to a specific full-recovery date, but current projections suggest the shortage may begin to ease in late Q3 or Q4 2026. The availability of two imported alternatives (Extencilline and Lentocilin) provides some buffer, though distribution is uneven across regions.

The structural vulnerability — a single domestic manufacturer for a critical public health medication — remains unaddressed. Advocacy organizations and public health agencies continue to call for policy reforms to prevent future single-source shortages of essential medications.

Final Thoughts

The Bicillin L-A shortage is a clinically significant challenge that requires proactive management. Providers should:

1. Monitor local supply status regularly
2. Familiarize themselves with imported alternative products and their preparation
3. Prioritize BPG for pregnant patients with syphilis
4. Document clinical rationale when using alternative regimens
5. Utilize tools like Medfinder for Providers to locate available stock

For the patient perspective on this shortage, see our companion article: Bicillin L-A Shortage: What Patients Need to Know in 2026. For practical guidance on helping patients navigate access challenges, read: How to Help Your Patients Find Bicillin L-A in Stock.